Adverse effects of hyperhomocysteinemia and their management by folic acid

Mineral and Electrolyte Metabolism

Volumn 23, Issue 3-6, 1997, Pages 174-178

  Perna, Alessandra F ^a   De Santo, Natale G ^b   Ingrosso, Diego ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NONE

Author keywords

Adenosylhomocysteine; Adenosylmethionine; Cardiovascular risk factors; Erythrocytes; Homocysteine; Methylation reactions; Uremia

Indexed keywords

DEXTRO ARGININE; FOLIC ACID; HOMOCYSTEINE; MEMBRANE PROTEIN; S ADENOSYLHOMOCYSTEINE;

CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; CYTOCHEMISTRY; ERYTHROCYTE MEMBRANE; HEMODIALYSIS PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; PRIORITY JOURNAL; UREMIA;

CARDIOVASCULAR DISEASES; FOLIC ACID; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; METHYLATION; RISK FACTORS; UREMIA;

EID: 0030723158     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Jakuboski H, Goldman E: Synthesis of homocysteine thiolactone by methionyl-tRNA synthetase in cultured mammalian cells. FEBS Lett 1993;317:237-240.
2. McCully KS: Chemical pathology of homocysteine. I. Atherogenesis. Ann Clin Lab Sci 1993;23:477-493.
3. Mudd SH, Levy HL, Skovby F: Disorders of transulfuration; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease. New York, Mc Graw Hill, 1989, p 693.
4. Selhub J, Miller JW: The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992;55:131-138.
5. Zappia V, Zydek-Cwick CR, Schlenk F: The specificity of S-adenosylmethionine derivatives in methyl transfer reactions. J Biol Chem l969;244:4499-4505.
6. Cantoni GL, Chiang PK: The role of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase in the control of biologic methylations; in Cavallini D, Gaull GE, Zappia V (eds): Natural Sulfur Compounds: Novel Biochemical and Structural Aspects. New York, Plenum, 1980, p 67.
7. Barber JR, Clarke S: Inhibition of protein carboxyl methylation by S-adenosyl-L-homocysteine in intact erythrocytes: Physiological consequences. J Biol Chem 1984;259:7115-7122.
8. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N: Thermolabile methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48:536-545.
9. Wilcken DEL, Wilcken B: The pathogenesis of coronary artery disease: A possible role for methionine metabolism. J Clin Invest 1976;57:1079-1082.
10. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155.
11. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
12. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G: Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: The atherosclerosis Risk in Communities Study. Circulation 1993;87:1107-1113.
13. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM, Kvale G: Total plasma homocysteine and cardiovascular risk profile: The Hordaland Homocysteine Study. JAMA 1995;274:1526-1533.
14. Robinson K, Mayer EL, Miller DP, Green R, Lente F van, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE, Kutner M, Topol EJ, Jacobsen DW: Hyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825-2830.
15. Harker LA, Ross R, Slichter SJ, Scott CR: Homocystine-induced arteriosclerosis: The role of endothelial cell injury and platelet response to its genesis. J Clin Invest 1976;58:731-741.
16. Oakley GP: Folic acid fortification - Prevention opportunity of the decade? Irish J Med Sci 1995; 164:S14.
17. Tsai C, Perrella MA, Yoshizumi M, Hsien CM, Habe E, Schlagel R, Lee ME: Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-6373.
18. Harpel PC, Chang VT, Bort W: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992;89:10193-10197.
19. Preibisch G, Kuffner C, Elstner EF: Biochemical model reactions on the prooxidative activity of homocysteine. J Biosci 1993;48:58-62.
20. Hajjar KA: Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873-2879.
21. Rodgers GM, Kane WH: Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986;77:1909-1916.
22. Hayashi T, Honda G, Suzuki K: An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992;79:2930-2936.
23. Parfrey PS: Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis 1993;21:77-80.
24. Wilcken DEL, Gupta VJ, Reddy SG: Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis. Clin Sci 1980;58:427-430.
25. Laidlaw SA, Smolin LA, Davidson WD, Kopple JD: Sulfur amino acids in maintenance hemodialysis patients. Kidney Int 1987;32:S191-S196.
26. Chauveau P, Chadefaux B, Coudé M, Aupetit J, Hannedouche T, Kamoun P, Jungers P: Increased plasma homocysteine concentration in patients with chronic renal failure. Miner Electrolyte Metab 1992;18:196-198.
27. Chauveau P, Chadefaux B, Coudé M, Aupetit J, Hannedouche T, Kamoun P, Jungers P: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993;43:S72-S77.
28. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995;6:121-125.
29. Robinson K, Gupta A, Dennis V, Arheart D, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and piridoxine concentrations. Circulation, 1996;94:2743-2748.
30. Dennis VW, Robinson K: Homocysteinemia and vascular disease in end stage renal disease. Kidney Int 1996;50:S11-S17.
31. Perna AF, Ingrosso D, De Santo NG, Galletti P, Zappia V: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995;47:247-253.
32. Perna AF, Ingrosso D, Galletti P, Zappia V, De Santo NG: Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure: Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin Invest 1993;91:2497-2503.
33. Galletti P, Ingrosso D, Manna C, Clemente G, Zappia V: Protein damage and methylation mediated repair in the erythrocyte. Biochem J 1995;306:313-325.
34. Perna AF, D'Aniello A, Lowenson JD, Clarke S, De Santo NG, Ingrosso D: D-aspartate content of erythrocyte membrane proteins is decreased in uremia: Implications for the repair of damaged proteins. J Am Soc Nephrol 1997;8:95-104.
35. Perna AF, Ingrosso D, Galletti P, Zappia V, De Santo NG: Membrane protein damage and methylation reactions in chronic renal failure. Kidney Int 1996;50:358-366.
36. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 1988;37:697-701.
37. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147-152.
38. Livant EJ, Tamura T, Johnston KE, Vaughn WH, Bergman SM, Forehand J, Walthaw J: Plasma folate conjugase activities and folate concentration in patients receiving hemodialysis. J Nutr Biochem 1994;5:504-508.
39. Krudieck CL, Eto I: Folate in tissues and cells: Support for a 'two tier' hypothesis of one carbon metabolism; in Cooper BA, Whitehead MV (eds): Chemistry and Biology of Pteridines. Berlin, Walter de Gruyter, 1986, pp 447-466.
40. Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 1993;40:230-234.
41. Perna AF, Ingrosso D, De Santo NG, Galletti P, Brunone M, Zappia V: Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol, in press.